The patients who had DBC1-expressing serous carcinoma had a 4.277-fold (P = 0.002, 95% CI; 1.674-10.926) greater risk of death and its expression was significantly associated with shorter RFS (P = 0.005, HR; 2.811, 95% CI; 1.363-5.794) (Figure 3C). This evidence concerns the gene CCAR2 and serous adenocarcinoma.